189 related articles for article (PubMed ID: 21792329)
1. Clinical relevance and treatment of nonautoimmune anemia in chronic lymphocytic leukemia.
Molica S; Mirabelli R; Molica M; Levato L; Mauro FR; Foà R
Cancer Manag Res; 2011; 3():211-7. PubMed ID: 21792329
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin and chronic lymphocytic leukemia.
Mauro FR; Gentile M; Foa R
Rev Clin Exp Hematol; 2002; Suppl 1():21-31. PubMed ID: 12735212
[TBL] [Abstract][Full Text] [Related]
3. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations.
Ludwig H; Rai K; Blade J; Dammacco F; Degos L; Itri L; Kyle R; Liso V; Littlewood TJ; Mandelli F; Meloni G; Molica S; Osterborg A; Pangalis GA; San Miguel J; Schmitt B; Voliotis D
Hematol J; 2002; 3(3):121-30. PubMed ID: 12111647
[TBL] [Abstract][Full Text] [Related]
4. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
5. Epoetin alfa therapy for patients with hematologic malignancies and mild anemia.
Straus DJ
Clin Lymphoma; 2003 Aug; 4 Suppl 1():S13-7. PubMed ID: 14556671
[TBL] [Abstract][Full Text] [Related]
6. Hemoglobin decline in cancer patients receiving chemotherapy without an erythropoiesis-stimulating agent.
Pirker R; Pirolli M; Quigley J; Hulnick S; Legg J; Collins H; Vansteenkiste J
Support Care Cancer; 2013 Apr; 21(4):987-92. PubMed ID: 23096072
[TBL] [Abstract][Full Text] [Related]
7. Erythropoiesis-stimulating agents for anemia in rheumatoid arthritis.
Martí-Carvajal AJ; Agreda-Pérez LH; Solà I; Simancas-Racines D
Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD000332. PubMed ID: 23450527
[TBL] [Abstract][Full Text] [Related]
8. Anemia in cancer patients: significance, epidemiology, and current therapy.
Tchekmedyian NS
Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):17-24. PubMed ID: 12380951
[TBL] [Abstract][Full Text] [Related]
9. Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia.
Frustaci AM; Del Poeta G; Visentin A; Sportoletti P; Fresa A; Vitale C; Murru R; Chiarenza A; Sanna A; Mauro FR; Reda G; Gentile M; Varettoni M; Baratè C; Borella C; Greco A; Deodato M; Zamprogna G; Laureana R; Cipiciani A; Galitzia A; Curto Pelle A; Morelli F; Malvisi L; Coscia M; Laurenti L; Trentin L; Montillo M; Cairoli R; Tedeschi A
Ther Adv Hematol; 2022; 13():20406207221127550. PubMed ID: 36246422
[TBL] [Abstract][Full Text] [Related]
10. Chronic lymphocytic leukemia: economic burden and quality of life: literature review.
Stephens JM; Gramegna P; Laskin B; Botteman MF; Pashos CL
Am J Ther; 2005; 12(5):460-6. PubMed ID: 16148431
[TBL] [Abstract][Full Text] [Related]
11. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
12. Intravenous iron monotherapy for the treatment of non-iron-deficiency anemia in cancer patients undergoing chemotherapy: a pilot study.
Abdel-Razeq H; Abbasi S; Saadi I; Jaber R; Abdelelah H
Drug Des Devel Ther; 2013; 7():939-44. PubMed ID: 24039403
[TBL] [Abstract][Full Text] [Related]
13. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies.
Straus DJ; Testa MA; Sarokhan BJ; Czuczman MS; Tulpule A; Turner RR; Riggs SA
Cancer; 2006 Oct; 107(8):1909-17. PubMed ID: 16977654
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human erythropoietin treatment for chemotherapy-related anemia in children.
Varan A; Büyükpamukçu M; Kutluk T; Akyüz C
Pediatrics; 1999 Feb; 103(2):E16. PubMed ID: 9925862
[TBL] [Abstract][Full Text] [Related]
15. Effect of reimbursement changes on erythropoiesis-stimulating agent utilization and transfusions.
Hess G; Nordyke RJ; Hill J; Hulnick S
Am J Hematol; 2010 Nov; 85(11):838-43. PubMed ID: 20976794
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the influence of various factors on anemia in patients with lymphoid malignancies.
Zupanić-Krmek D; Lang N; Jurcić D; Ljubić N; Bilić A
Acta Clin Croat; 2011 Dec; 50(4):495-500. PubMed ID: 22649879
[TBL] [Abstract][Full Text] [Related]
17. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
[TBL] [Abstract][Full Text] [Related]
18. Chinese physician perception on the treatment of chemotherapy-induced anemia: online cross-section survey study.
Zhang J; Du Y; Meng Y; Liu X; Mu Y
Chin Clin Oncol; 2024 Feb; 13(1):5. PubMed ID: 38453656
[TBL] [Abstract][Full Text] [Related]
19. Benefits of early intervention with erythropoiesis- stimulating proteins in chemotherapy-induced anemia.
Lyman GH
Oncology (Williston Park); 2006 Jul; 20(8 Suppl 6):16-20. PubMed ID: 16925106
[TBL] [Abstract][Full Text] [Related]
20. An economic evaluation of erythropoiesis-stimulating agents in CKD.
Clement FM; Klarenbach S; Tonelli M; Wiebe N; Hemmelgarn B; Manns BJ
Am J Kidney Dis; 2010 Dec; 56(6):1050-61. PubMed ID: 20932621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
